Immune checkpoint inhibitors: a new frontier in bladder cancer

被引：15
|
作者：
Kates, Max [1 ,2 ]
Sopko, Nikolai A. [1 ,2 ]
Matsui, Hotaka [1 ,2 ]
Drake, Charles G. [1 ,2 ]
Hahn, Noah M. [1 ,2 ]
Bivalacqua, Trinity J. [1 ,2 ]
机构：
[1] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, 1800 Orleans St,Marburg 420, Baltimore, MD 21287 USA
[2] Johns Hopkins Sch Med, Dept Urol, 1800 Orleans St,Marburg 420, Baltimore, MD 21287 USA
来源：
WORLD JOURNAL OF UROLOGY | 2016年 / 34卷 / 01期
基金：
美国国家卫生研究院;
关键词：
Immune checkpoint; Bladder cancer; Tumor immunology; BACILLUS-CALMETTE-GUERIN; PD-1; BLOCKADE; UROTHELIAL CARCINOMA; ANTI-PD-L1; ANTIBODY; ANTITUMOR IMMUNITY; ADVANCED MELANOMA; IFN-GAMMA; CTLA-4; EXPRESSION; SAFETY;
D O I：
10.1007/s00345-015-1709-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.
引用
收藏
页码：49 / 55
页数：7
相关论文
共 50 条
  • [11] Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
    Clarke, Jeffrey M.
    George, Daniel J.
    Lisi, Stacey
    Salama, April K. S.
    [J]. TARGETED ONCOLOGY, 2018, 13 (01) : 1 - 20
  • [12] Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
    Jeffrey M. Clarke
    Daniel J. George
    Stacey Lisi
    April K. S. Salama
    [J]. Targeted Oncology, 2018, 13 : 1 - 20
  • [13] PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?
    Al-Ahmadie, H.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (09) : 1658 - 1659
  • [14] Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
    El-Osta, Hazem
    Shahid, Kamran
    Mills, Glenn M.
    Peddi, Prakash
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 5101 - 5116
  • [15] Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences
    Liblik, Kiera
    Caterini, Jessica
    Touma, Naji J.
    [J]. UROLOGY, 2024, 187 : 114 - 118
  • [16] IMMUNE CHECKPOINT INHIBITORS FOR KIDNEY AND BLADDER CANCER: ADRENOTOXIC CONSEQUENCES
    Liblik, Kiera
    Caterini, Jessica
    Touma, Naji
    [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E528 - E528
  • [17] Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a 'New Frontier'?
    Pilotto, Sara
    Kinspergher, Stefania
    Peretti, Umberto
    Calio, Anna
    Carbognin, Luisa
    Ferrara, Roberto
    Brunelli, Matteo
    Chilosi, Marco
    Tortora, Giampaolo
    Bria, Emilio
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (03) : 307 - 313
  • [18] Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
    Saachi Chhaya
    Isabella Watts
    Kenrick Ng
    Rami Mustapha
    Thomas Powles
    Anand Sharma
    Nikhil Vasdev
    [J]. Oncology and Therapy, 2023, 11 : 49 - 64
  • [19] Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
    Maiorano, Brigida Anna
    De Giorgi, Ugo
    Ciardiello, Davide
    Schinzari, Giovanni
    Cisternino, Antonio
    Tortora, Giampaolo
    Maiello, Evaristo
    [J]. BIOMEDICINES, 2022, 10 (02)
  • [20] Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence
    Okobi, Tobechukwu J.
    Uhomoibhi, Trinitas Oserefuamen
    Akahara, Darlington E.
    Odoma, Victor A.
    Sanusi, Ibilola A.
    Okobi, Okelue E.
    Umana, Ifiok
    Okobi, Emeka
    Okonkwo, Chinwe C.
    Harry, Nkechinyere M.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)
12345